title: [Role of ciclesonide in asthma therapy].
abstract: Ciclesonide is a modern inhaled corticosteroid registered for asthma treatment. It is delivered as an inactive prodrug and undergoes conversion to an active metabolite in the lungs. Ciclesonide has been formulated as an aerosol solution in a metered dose inhaler with hydrofluoralkane which characterizes a high deposition rate over 50%. Lots of clinical trials show that ciclesonide is effective in asthma control in a wide range of doses from 40 do 1280 mug/day in a dose-dependent manner. It reduces the need for systemic corticosteroids. Due to the unique pharmacokinetics, ciclesonide has a favorable safety profile both in the low and in the high doses. It is recommended by GINA in every case when the glucocorticosteroids are indicated, as a drug with reduced local and systemic side effects. This article is a review of clinical trials on efficacy and safety of ciclesonide as the resume of authors' clinical experience.
authors.affiliation: Klinika Chorób Wewnetrznych, Astmy i Alergii, Uniwersytecki Szpital Kliniczny nr 1 im. Lodzi. ikuprys@wp.pl
authors.forename: Izabela
authors.initials: I
authors.lastname: Kupryś-Lipińska
authors.forename: Piotr
authors.initials: P
authors.lastname: Kuna
mesh_terms: D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D036501:Metered Dose Inhalers; D011282:Pregnenediones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D011282:Pregnenediones; C120481:ciclesonide